Focalin XR: Phase III data

In a double-blind, placebo-controlled, U.S. Phase III trial in 103 patients aged 6 to 17 years, the mean change from baseline in CADS-T score for Focalin XR was 16.3 compared to 5.9 for placebo (p<0.0...